[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-363748-105":59,"doc-detail-363748-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","sex-based-differences-in-tolerability-of-developmental-antibody-drug-conjugates-adcs-in-non-small-cell-lung-cancer-nsclc","Sex-based differences in tolerability of developmental antibody-drug conjugates (ADCs) in non-small-cell lung cancer (NSCLC)","","Sex-disaggregated safety evidence for antibody-drug conjugates (ADCs) in non-small-cell lung cancer (NSCLC) is limited. This monocentric cohort study evaluated clinically significant treatment-related adverse events (TRAEs, grade ≥2; CTCAE v5.0), dose modifications, hospitalisations, and survival among advanced NSCLC patients receiving developmental ADCs in phase I–II trials at Gustave Roussy (2018–2023). Women showed higher TRAE burden, including higher grade ≥2 incidence and metabolic TRAEs, plus more dose reductions.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/sex-based-differences-in-tolerability-of-developmental-antibody-drug-conjugates-adcs-in-non-small-cell-lung-cancer-nsclc/363748/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/sex-based-differences-in-tolerability-of-developmental-antibody-drug-conjugates-adcs-in-non-small-cell-lung-cancer-nsclc/363748.png","ImageObject",300,407,{"name":92,"@type":93},"Well Done","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-01","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":52},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why study sex differences in ADC tolerability for NSCLC?","Question",{"text":112,"@type":113},"Sex-based differences in treatment-related adverse events have been reported across anticancer therapies, but sex-disaggregated safety data for ADCs in NSCLC was lacking, motivating this study.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How was the study conducted and what outcomes were assessed?",{"text":117,"@type":113},"A monocentric cohort included advanced NSCLC patients treated with developmental ADCs in phase I–II trials at Gustave Roussy (2018–2023). Clinically significant TRAEs (grade ≥2, CTCAE v5.0), dose modifications, hospitalisations, and survival were analysed by sex using univariate and multivariate methods.",{"name":119,"@type":110,"acceptedAnswer":120},"What were the main findings regarding women versus men?",{"text":121,"@type":113},"Women had a higher incidence of grade ≥2 TRAEs than men and a higher median number of TRAEs. Metabolic TRAEs and dose reductions were also more frequent in women.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},363748,1790344208,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":52,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":39,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":46,"preview_page_count":19,"preview_urls":144},5909892210082,"https://ap-avatar.wpscdn.com/avatar/56001069da27c9f41e8?x-image-process=image/resize,m_fixed,w_180,h_180&k=1789614185077863061","ORIGINAL ARTICLE  \nSex-based differences in tolerability of developmental antibody-drug conjugates (ADCs) in non-small-cell lung cancer (NSCLC)  \nC. Parisi1 , 2 , 3∗‡, M. Banini4‡, F. Mantuano5, M. Aldea1 , 2, P. Abdayem1, L. Derosa1 , 2, M. Frelaut1, P. Lavaud1, A. Robert1, S. Simon6, A. Gazzah7, A. Hollebecque7, C. Massard7, B. Besse1 , 2, J. Remon1 , 2, A. Wagner8, B. Pistilli4 , 9 , 10, I. Vaz-Luis4 , 11,  \nD. Planchard1 , 2 & F. Barlesi1 , 2  \n1Department of Medical Oncology, International Centre for Thoracic Cancers (CICT), Gustave Roussy, Villejuif; 2Faculty of Medicine, University of Paris-Saclay, Kremlin-Bicêtre, France; 3Department of Medical and Surgical Sciences and Translational Medicine, St Andrea University Hospital, Sapienza University, Rome; 4Department of Radiation Oncology, AOUC — Azienda Ospedaliero-Universitaria Careggi, Firenze; 5Department of Medical and Surgical Sciences DIMEC, Alma Mater Studiorum University, Bologna, Italy; 6Clinical Research, Institut Gustave Roussy, Villejuif; 7Drug Development Department (DITEP), Institut Gustave Roussy, Villejuif, France; 8Department of Oncology, Gastrointestinal Cancer Clinic, University Hospital of Lausanne, Lausanne, Switzerland; 9INSERM 1279, Gustave Roussy, Villejuif; 10IHU PRISM National PRecISion Medicine Center in Oncology, Gustave Roussy, Villejuif; 11INSERM Unit 981-Molecular Predictors and New Targets in Oncology, Gustave Roussy, University Paris-Saclay, Villejuif, France  \nAvailable online xxx  \nBackground: Sex-based differences in treatment-related adverse events (TRAEs) have been described across several anticancer therapies. However, sex-disaggregated safety data for antibody-drug conjugates (ADCs) in non-small-cell lung cancer (NSCLC) is lacking.  \nPatients and methods: We conducted a monocentric cohort study including patients with advanced NSCLC treated with developmental ADCs within phase I-II clinical trials at Gustave Roussy (2018-2023) . Clinically significant TRAEs (grade ≥2, Common Terminology Criteria for Adverse Events version 5.0), dose modifications, hospitalisations, and survival outcomes were analysed according to sex using univariate and multivariate analysis.  \nResults: Our population included 132 patients [women, 64 (48 .5%); men, 68 (51 .5%)] receiving ADCs targeting TROP2 (32 .6%), ITGB6 (31 .8%), HER2 (13 .6%), CEACAM5 (13 .6%), HER3 (5 .4%), c-MET (2 .3%), and Nectin-4 (0 .7%) . Overall, 100 (76%) and 39 (29%) patients experienced grade ≥2 and grade ≥3 TRAEs, respectively. Women had a higher incidence of grade ≥2 TRAEs than men [82 .8% versus 69. 1%; adjusted odds ratio (OR) 2.8, 95% confidence interval (CI) 1.03-7.84, P = 0.04)] and a higher median number of TRAEs (2 versus 1, P = 0.04) . Metabolic TRAEs (anorexia, weight loss, ion and lipid imbalances) were significantly more frequent in women (29 .7% versus 10.3%; OR 3.68, 95% CI 1.42-9.49, P = 0.009), as were dose reductions (37 .5% versus 19. 1%; OR 3.35, 95% CI 1.24-9.01, P = 0.02) .  \nConclusions: Women treated with developmental ADCs for advanced NSCLC experience a higher burden of clinically relevant TRAEs. Our data suggest that sex may represent a key variable to integrate into safety reporting and monitoring strategies for developmental ADCs in NSCLC.  \nKey words: adverse events, AEs, antibody-drug conjugates, ADCs, clinical trials, non-small-cell lung cancer, NSCLC, sex, gender  \nINTRODUCTION  \nAntibody-drug conjugates (ADCs) represent a novel therapeutic class in lung cancer, combining target specificity with potent cytotoxic payload. By exploiting the overexpression  \n*Correspondence to: Dr Claudia Parisi, Department of Medical Oncology, International Centre for Thoracic Cancers (CICT), Gustave Roussy, 94805 Villejuif, France. Tel: +33 0766510321  \nE-mail: [claudia.PARISI@gustaveroussy.fr](claudia.PARISI@gustaveroussy.fr) (C. Parisi).  \n‡Both authors contributed equally.  \n2059-7029/© 2026 The Author(s). Published by Elsevier Ltd on behalf of European Society for ","cbCaikMHgCU79s4L","https://ap.wps.com/l/cbCaikMHgCU79s4L","pdf",1652186,"English","# Background\n# Patients and methods\n# Results\n# Conclusions\n# Key words\n# Introduction","[{\"question\":\"Why study sex differences in ADC tolerability for NSCLC?\",\"answer\":\"Sex-based differences in treatment-related adverse events have been reported across anticancer therapies, but sex-disaggregated safety data for ADCs in NSCLC was lacking, motivating this study.\"},{\"question\":\"How was the study conducted and what outcomes were assessed?\",\"answer\":\"A monocentric cohort included advanced NSCLC patients treated with developmental ADCs in phase I–II trials at Gustave Roussy (2018–2023). Clinically significant TRAEs (grade ≥2, CTCAE v5.0), dose modifications, hospitalisations, and survival were analysed by sex using univariate and multivariate methods.\"},{\"question\":\"What were the main findings regarding women versus men?\",\"answer\":\"Women had a higher incidence of grade ≥2 TRAEs than men and a higher median number of TRAEs. Metabolic TRAEs and dose reductions were also more frequent in women.\"}]","Sex-based differences in tolerability of developmental antibody-drug conjugates (ADCs) in non-small-cell lung cancer (NSCLC) | PDF",1790152965,[145,149,153,157],{"page_no":8,"url":146,"width":147,"height":148},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/af7efbd85095d7dee4d4006a1fdc517c.webp",983,1269,{"page_no":14,"url":150,"width":151,"height":152},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/92b44bbf6948ea0f805dc4e0515cd3c6.webp",982,1268,{"page_no":81,"url":154,"width":155,"height":156},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e6ef1b4ec958f86fa823c99b1ebf08ef.webp",981,1266,{"page_no":19,"url":158,"width":159,"height":160},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/98f1e952c6fa19d655eddbb6a974d387.webp",980,1265]